Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria

被引:143
作者
Falagas, ME [1 ]
Bliziotis, IA
Kasiakou, SK
Samonis, G
Athanassopoulou, P
Michalopoulos, A
机构
[1] Alfa Inst Biomed Sci, Athens, Greece
[2] Tufts Univ, Sch Med, Boston, MA 02111 USA
[3] Alfa Healthcare, Athens, Greece
[4] Univ Crete, Sch Med, Univ Hosp, Dept Med, Iraklion, Greece
[5] Henry Dunant Hosp, Intens Care Unit, Athens, Greece
关键词
D O I
10.1186/1471-2334-5-24
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: The increasing problem of infections due to multidrug-resistant Gram-negative bacteria has led to re-use of polymyxins in several countries. However, there are already clinical isolates of Gram-negative bacteria that are resistant to all available antibiotics, including polymyxins. Methods: We present a case series of patients with infections due to pathogens resistant to all antimicrobial agents tested, including polymyxins. An isolate was defined as pandrug-resistant (PDR) if it exhibited resistance to all 7 anti-pseudomonal antimicrobial agents, i.e. antipseudomonal penicillins, cephalosporins, carbapenems, monobactams, quinolones, aminoglycosides, and polymyxins. Results: Clinical cure of the infection due to pandrug-resistant ( PDR) Gram-negative bacteria, namely Pseudomonas aeruginosa or Klebsiella pneumoniae was observed in 4 out of 6 patients with combination of colistin and beta lactam antibiotics. Conclusion: Colistin, in combination with beta lactam antibiotics, may be a useful agent for the management of pandrug-resistant Gram-negative bacterial infections. The re-use of polymyxins, an old class of antibiotics, should be done with caution in an attempt to delay the rate of development of pandrug-resistant Gram-negative bacterial infections.
引用
收藏
页数:7
相关论文
共 27 条
[1]  
[Anonymous], HOSP EPIDEMIOLOGY IN
[2]   Temperature-regulated efflux pump/potassium antiporter system mediates resistance to cationic antimicrobial peptides in Yersinia [J].
Bengoechea, JA ;
Skurnik, M .
MOLECULAR MICROBIOLOGY, 2000, 37 (01) :67-80
[3]   A reassessment of the in-vitro activity of colistin sulphomethate sodium [J].
Catchpole, CR ;
Andrews, JM ;
Brenwald, N ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (02) :255-260
[4]   Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients:: antibiotic resistance, β-lactamase activity and RiboPrinting [J].
Ciofu, O ;
Fussing, V ;
Bagge, N ;
Koch, C ;
Hoiby, N .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (03) :391-396
[5]   Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center [J].
Denton, M ;
Kerr, K ;
Mooney, L ;
Keer, V ;
Rajgopal, A ;
Brownlee, K ;
Arundel, P ;
Conway, S .
PEDIATRIC PULMONOLOGY, 2002, 34 (04) :257-261
[6]  
FALAGAS ME, 2005, IN PRESS CLIN INFECT
[7]   Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines [J].
Gales, AC ;
Reis, AO ;
Jones, RN .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (01) :183-190
[8]   Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin:: A comparison with imipenem-susceptible VAP [J].
Garnacho-Montero, J ;
Ortiz-Leyba, C ;
Jiménez-Jiménez, FJ ;
Barrero-Alodóvar, AE ;
García-Garmendia, JL ;
Bernabeu-Witteli, M ;
Gallego-Lara, SL ;
Madrazo-Osuna, J .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (09) :1111-1118
[9]   In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa [J].
Giamarellos-Bourboulis, EJ ;
Sambatakou, H ;
Galani, I ;
Giamarellou, H .
JOURNAL OF CHEMOTHERAPY, 2003, 15 (03) :235-238
[10]   Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia [J].
Giamarellos-Bourboulis, EJ ;
Karnesis, L ;
Giamarellou, H .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (03) :259-263